Esophagus最新文献

{"title":"Prognostic impact of endoscopic response evaluation after neoadjuvant chemotherapy for esophageal squamous cell carcinoma: a nationwide validation study.","authors":"Satoru Matsuda,&nbsp;Yuko Kitagawa,&nbsp;Jun Okui,&nbsp;Akihiko Okamura,&nbsp;Hirofumi Kawakubo,&nbsp;Ryo Takemura,&nbsp;Koji Kono,&nbsp;Manabu Muto,&nbsp;Yoshihiro Kakeji,&nbsp;Hiroya Takeuchi,&nbsp;Masayuki Watanabe,&nbsp;Yuichiro Doki","doi":"10.1007/s10388-023-00998-x","DOIUrl":"https://doi.org/10.1007/s10388-023-00998-x","url":null,"abstract":"<p><strong>Background: </strong>Our previous study reported the prognostic significance of endoscopic response (ER) evaluation, defined ER, and revealed ER as an independent prognostic factor of overall survival (OS) and recurrence-free survival (RFS) for esophageal squamous cell carcinoma (ESCC) treated with neoadjuvant chemotherapy (NAC) and surgery. The present study aimed to validate the prognostic impact of ER using a nationwide database from the authorized institute for board-certified esophageal surgeons by the Japan Esophageal Society.</p><p><strong>Methods: </strong>This study retrospectively reviewed patients with ESCC who underwent subtotal esophagectomy at 85 authorized institutes for esophageal cancer from 2010 to 2015. Patients were classified as ER when the tumor size was markedly reduced post-NAC compared to pre-NAC. The correlation between OS and RFS was investigated.</p><p><strong>Results: </strong>Of 4781 patients initially enrolled, 3636 were selected for subsequent analysis. Of them, 642 (17.7%) patients were classified as the ER group. Patients with ER showed significantly better OS and RFS. Subgroup analysis revealed the statistical difference in OS and RFS in cStage II and III, while the magnitude of survival difference between ER and non-ER was not evident in cStage I and IV. The percentage of ER varied from 46 to 87% among groups when institutions were classified into 3 subgroups based on the hospital volume, which would indicate the interinstitutional inconsistency.</p><p><strong>Conclusions: </strong>The prognostic impact of ER was validated using a nationwide database. Standardization of ER evaluation is required to improve the interinstitutional consistency and clinical validity of the ER evaluation.</p>","PeriodicalId":11918,"journal":{"name":"Esophagus","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9629415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential prognostic significance of sarcopenia in metastatic esophageal squamous and adenocarcinoma.","authors":"Ulf Zeuge,&nbsp;Aline F Fares,&nbsp;Joelle Soriano,&nbsp;Katrina Hueniken,&nbsp;Jaspreet Bajwa,&nbsp;Wanning Wang,&nbsp;Sabine Schmid,&nbsp;Sarah Rudolph-Naiberg,&nbsp;M Catherine Brown,&nbsp;Jonathan Yeung,&nbsp;Eric X Chen,&nbsp;Raymond W Jang,&nbsp;Wei Xu,&nbsp;Elena Elimova,&nbsp;Geoffrey Liu,&nbsp;Dmitry Rozenberg,&nbsp;Micheal C McInnis","doi":"10.1007/s10388-022-00981-y","DOIUrl":"https://doi.org/10.1007/s10388-022-00981-y","url":null,"abstract":"<p><strong>Background: </strong>Sarcopenia indicates poor prognosis in various malignancies. We evaluated the association of sarcopenia with overall (OS) and progression-free survival (PFS) in metastatic esophageal cancer (MEC) patients, a population often presenting with poor nutritional status.</p><p><strong>Methods: </strong>In newly diagnosed MEC patients managed at the Princess Margaret (PM) Cancer Centre (diagnosed 2006-2015), total muscle area, visceral adiposity (VA), and subcutaneous adiposity (SA) were quantified on abdominal computed tomography at L3. Sarcopenia was determined using published cutoffs, based on sex and height.</p><p><strong>Results: </strong>Of 202 MEC patients, most were male (166/82%), < 65 years (116/57%), and had adenocarcinoma histology (141/70%); 110/54% had recurrent MEC after initial curative-intent treatment; 92/46% presented with de novo MEC. At stage IV diagnosis, 20/10% were underweight, 97/48% were normal-weight and 84/42% were overweight/obese; 103/51% were sarcopenic. Sarcopenia was associated with worse median OS (4.6 vs. 7.9 months; log-rank p = 0.03) and 1-year survival, even after adjusting for other body composition variables (e.g., BMI, VA, and SA): adjusted-HR 1.51 [95% CI 1.1-2.2, p = 0.02]. In post hoc analysis, sarcopenia was highly prognostic in adenocarcinomas (p = 0.003), but not squamous cell carcinomas (SCC). In patients receiving palliative systemic treatment (104/51%), sarcopenia was associated with shorter PFS (p = 0.004) in adenocarcinoma patients (75/72%).</p><p><strong>Conclusions: </strong>In metastatic esophageal adenocarcinomas, sarcopenia is associated with worse PFS and OS. In metastatic esophageal SCC, there was a non-significant trend for worse PFS but no association with OS. In order to offset the poor prognosis associated with sarcopenia particularly in metastatic esophageal adenocarcinoma patients, future research should focus on possible countermeasures.</p>","PeriodicalId":11918,"journal":{"name":"Esophagus","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9566978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic impact of desmoplastic reaction in esophageal squamous cell carcinoma patients with neoadjuvant therapy.","authors":"Keita Kouzu,&nbsp;Yoshiki Kajiwara,&nbsp;Hironori Tsujimoto,&nbsp;Satsuki Mochizuki,&nbsp;Koichi Okamoto,&nbsp;Eiji Shinto,&nbsp;Yoji Kishi,&nbsp;Susumu Matsukuma,&nbsp;Hideki Ueno","doi":"10.1007/s10388-023-00996-z","DOIUrl":"https://doi.org/10.1007/s10388-023-00996-z","url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to examine the prognostic value of desmoplastic reaction (DR) in esophageal squamous cell carcinoma (ESCC), particularly in patients who received neoadjuvant therapy, such as chemotherapy (NAC) or chemoradiotherapy (NACRT).</p><p><strong>Method: </strong>In total, 153 patients with pStage II/III ESCC were included in this study. Ninety-one patients received neoadjuvant therapy (NAC, 70; NACRT, 21). Patients were classified according to three DR categories based on the presence of keloid-like collagen and/or myxoid stroma.</p><p><strong>Results: </strong>In total, 50, 50, and 53 patients were classified as having mature, intermediate, and immature DR, respectively. The weighted kappa coefficient was 0.623 in the patients with preoperative treatments and 0.782, in those without. The 5-year disease-specific survival (DSS) rates in patients with intermediate/immature DR was significantly worse than those with mature DR (40.7% vs. 73.3%, p < 0.001). Similarly, the 5-year DSS rate in patients with intermediate/immature DR was significantly worse than those with mature DR in a study of patients who received neoadjuvant therapy (46.7% vs. 71.2%, p = 0.009). Multivariate analysis revealed that DR (hazard ratio [HR]: 3.15, 95% confidence interval [CI] 1.58-6.27, p = 0.001), along with N factors, was an independent risk factor for DSS. Moreover, multivariate analysis of patients who received neoadjuvant therapy revealed only DR (HR: 2.47, 95% CI 1.02-5.96, p = 0.045) as independent risk factors for DSS.</p><p><strong>Conclusion: </strong>The DR classification was a valuable prognostic factor not only in the ESCC patients without neoadjuvant therapy but also in those with neoadjuvant therapy.</p>","PeriodicalId":11918,"journal":{"name":"Esophagus","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9629397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of combined PD-L1 positive score on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinoma.","authors":"Yuki Matsubara,&nbsp;Kazuhiro Toriyama,&nbsp;Shigenori Kadowaki,&nbsp;Takatsugu Ogata,&nbsp;Taiko Nakazawa,&nbsp;Kyoko Kato,&nbsp;Kazuki Nozawa,&nbsp;Yukiya Narita,&nbsp;Kazunori Honda,&nbsp;Toshiki Masuishi,&nbsp;Hideaki Bando,&nbsp;Masashi Ando,&nbsp;Masahiro Tajika,&nbsp;Isao Oze,&nbsp;Waki Hosoda,&nbsp;Kei Muro","doi":"10.1007/s10388-022-00978-7","DOIUrl":"https://doi.org/10.1007/s10388-022-00978-7","url":null,"abstract":"<p><strong>Background: </strong>Nivolumab is recommended for patients with advanced esophageal squamous cell carcinoma (aESCC) refractory or intolerant to fluoropyrimidine- and platinum-based chemotherapy regardless of the tumor proportion score (TPS). However, the role of combined positive score (CPS) in predicting nivolumab efficacy remains unclear. We aimed to study whether TPS or CPS is a more suitable biomarker for predicting nivolumab efficacy in these patients.</p><p><strong>Methods: </strong>We retrospectively collected data from patients with aESCC treated with fluoropyrimidines and platinum and subsequently received nivolumab monotherapy between January 1, 2014 and September 15, 2020. Next, we evaluated the efficiencies of TPS and CPS in predicting the clinical response to nivolumab using PD-L1 IHC 22C3 pharmDx assay.</p><p><strong>Results: </strong>This study included 50 patients (CPS groups: ≥ 10/1-10/ < 1, n = 24/18/8, respectively; TPS groups, ≥ 10%/1%-10%/ < 1%, n = 17/8/25, respectively). The median progression-free survival was 3.2, 2.5, and 1.5 months in the ≥ 10, 1-10 [hazard ratio (HR) vs. CPS of ≥ 10 group, 1.01; p = 0.98; adjusted HR, 1.33; p = 0.56], and < 1 CPS groups (HR vs. CPS of ≥ 10 group, 3.44; p = 0.006; adjusted HR, 1.67; p = 0.41), respectively. For the patients with CPS of ≥ 10/1-10/ < 1 and TPS of ≥ 10%/1%-10%/ < 1%, the objective response rate was 30%/25%/0% and 36%/0%/19% and the disease control rate was 60%/50%/12% (p = 0.06) and 65%/40%/38% (p = 0.30), respectively.</p><p><strong>Conclusions: </strong>This study suggests that a CPS of < 1 is not a strong predictor of efficacy but can predict the absence of response to nivolumab in patients with aESCC.</p>","PeriodicalId":11918,"journal":{"name":"Esophagus","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9930679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of the difficulty of transcervical subcarinal lymph node dissection for esophageal cancer.","authors":"Hirotaka Furuke, Hirotaka Konishi, Hitoshi Fujiwara, Atsushi Shiozaki, Takuma Ohashi, Hiroki Shimizu, Tomohiro Arita, Yusuke Yamamoto, Ryo Morimura, Yoshiaki Kuriu, Hisashi Ikoma, Takeshi Kubota, Kazuma Okamoto, Eigo Otsuji","doi":"10.1007/s10388-022-00983-w","DOIUrl":"10.1007/s10388-022-00983-w","url":null,"abstract":"<p><strong>Background: </strong>Transmediastinal radical esophagectomy (TME) is a new minimally invasive approach without thoracotomy. However, the transcervical dissection of subcarinal lymph nodes (SCLN) is challenging. The shape or narrowness of the mediastinal space, particularly around the aortic arch to the tracheal bifurcation, may increase the difficulty of this procedure. The present study aimed to clarify predictors of the difficulty of transcervical SCLN dissection.</p><p><strong>Methods: </strong>Patients who underwent TME between 2016 and 2019 were included (n = 126). Four indicators, the cervical angle, carina distance, aorta distance, and sternum distance, were defined as indicators of mediastinal narrowness by 3D-CT. The relationships between the difficulty of transcervical SCLN dissection and clinicopathological features, including the above indicators, were investigated.</p><p><strong>Results: </strong>In a univariate analysis, the cervical angle (p = 0.023), aorta distance (p = 0.002), and middle thoracic tumor (p = 0.040) correlated with difficulty. The median cervical angle and aorta distance were 15° and 33 mm in difficult cases and 19° and 43 mm in easy cases, respectively. In a multivariate analysis, the short aorta distance (odds ratio: 7.96, p = 0.002) and middle thoracic tumor (odds ratio: 3.35, p = 0.042) were independent predictive factors.</p><p><strong>Conclusions: </strong>The cervical angle, aorta distance, and middle thoracic tumor may predict the difficulty of transcervical SCLN dissection. In difficult cases, a transhiatal approach should be combined for complete SCLN dissection.</p>","PeriodicalId":11918,"journal":{"name":"Esophagus","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234892/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9573405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical predictors of special type of esophageal cancer.","authors":"Yugo Suzuki,&nbsp;Yu Ohkura,&nbsp;Mako Koseki,&nbsp;Kosuke Nomura,&nbsp;Akira Matsui,&nbsp;Masaki Ueno,&nbsp;Daisuke Kikuchi,&nbsp;Kenichi Ohashi,&nbsp;Shu Hoteya","doi":"10.1007/s10388-023-01003-1","DOIUrl":"https://doi.org/10.1007/s10388-023-01003-1","url":null,"abstract":"<p><strong>Background: </strong>Esophageal cancers with a histological type other than the two major types, squamous cell carcinoma (SCC) and adenocarcinoma, are referred to as \"special type of esophageal cancer\" (STEC). STEC is rare and difficult to diagnose preoperatively. Therefore, we aimed to clarify the clinicopathological findings of STEC, including magnifying endoscopy with narrow band imaging (ME-NBI).</p><p><strong>Methods: </strong>We reviewed 1133 lesions in 936 consecutive cases who underwent endoscopic resection or surgical resection for primary esophageal cancer. Patients were classified into the SCC group and the STEC group, respectively. Factors that predict STEC endoscopically, as well as clinicopathologic features of STEC compared to SCC, were examined.</p><p><strong>Results: </strong>Twenty-eight STECs were diagnosed in 28 patients: 15 with basaloid squamous cell carcinoma, 6 with adenosquamous carcinoma, 4 with mucoepidermoid carcinoma, 1 with carcinosarcoma, 1 with salivary duct-type carcinoma, and 1 with neuroendocrine cell carcinoma. There was significantly more pT1b or deeper cancer (60.7% vs. 12.8%), lymphovascular invasion (50.0% vs. 11.1%) and elevated type (53.6% vs. 16.1%) in the STEC group. The proportion of lesions with type R vessels on ME-NBI was significantly higher in the STEC group (46.4% vs. 3.9%). The STEC group had significantly lower accuracy of ME-NBI for prediction of depth (64.3% vs. 83.5%) and a greater proportion of underestimated lesions (32.1% vs. 9.3%). In the multivariate analysis, the histopathology of STEC was associated with type R vessels on ME-NBI.</p><p><strong>Conclusion: </strong>Type R vessels and submucosal tumor-like elevation might be the clinical predictors of STEC.</p>","PeriodicalId":11918,"journal":{"name":"Esophagus","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9931749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Simultaneous regulation of ferroptosis suppressor protein 1 and glutathione peroxidase 4 as a new therapeutic strategy of ferroptosis for esophageal squamous cell carcinoma.","authors":"Wataru Miyauchi,&nbsp;Yuji Shishido,&nbsp;Yoshiaki Matsumi,&nbsp;Tomoyuki Matsunaga,&nbsp;Masahiro Makinoya,&nbsp;Shota Shimizu,&nbsp;Kozo Miyatani,&nbsp;Teruhisa Sakamoto,&nbsp;Yoshihisa Umekita,&nbsp;Toshimichi Hasegawa,&nbsp;Yoshiyuki Fujiwara","doi":"10.1007/s10388-022-00982-x","DOIUrl":"https://doi.org/10.1007/s10388-022-00982-x","url":null,"abstract":"<p><strong>Background: </strong>Ferroptosis suppressor protein 1 and glutathione peroxidase 4 have been identified as key molecules in two independent pathways associated with ferroptosis inhibition. This study investigated the prognostic significance and clinical associations of FSP1 and GPX4 expression in esophageal squamous cell carcinoma (ESCC) and assessed the therapeutic potential of regulating these molecules in ESCC cells.</p><p><strong>Methods: </strong>Immunohistochemical analysis was performed on surgical specimens of 97 patients with ESCC for FSP1 and GPX4 expression. To identify the change in ESCC cell viability, FSP1 and GPX4 inhibitors were administered to three cell lines. In addition, ferroptosis as the cause of reduced cell viability by FSP1 and GPX4 inhibition was confirmed.</p><p><strong>Results: </strong>Prognosis was significantly worse for patients in the group positive for both FSP1 and GPX4 compared with the other groups (p < 0.001). In multivariate analysis, positivity for both FSP1 and GPX4 was an independent poor prognostic factor (p = 0.002). The combination of FSP1 and GPX4 inhibitors induced cell death more potently than each inhibitor did alone. Furthermore, the ferroptosis inhibitor markedly canceled this cell death.</p><p><strong>Conclusions: </strong>Overexpression of FSP1 and GPX4 is a poor prognostic factor for patients with ESCC. Simultaneous suppression of both FSP1 and GPX4 caused potent cell death, which was markedly abrogated by ferroptosis inhibitors. These findings indicate that simultaneous regulation of FSP1 and GPX4 may be a new therapeutic target in ESCC.</p>","PeriodicalId":11918,"journal":{"name":"Esophagus","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234947/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9947269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of solitary postoperative recurrence of esophageal squamous cell carcinoma diagnosed with FDG-PET/CT and treated with definitive radiation therapy.","authors":"Hiroki Ihara,&nbsp;Kotaro Yoshio,&nbsp;Shunsuke Tanabe,&nbsp;Soichi Sugiyama,&nbsp;Masashi Hashimoto,&nbsp;Naoaki Maeda,&nbsp;Shinsuke Akagi,&nbsp;Soshi Takao,&nbsp;Kazuhiro Noma,&nbsp;Takao Hiraki","doi":"10.1007/s10388-023-01000-4","DOIUrl":"https://doi.org/10.1007/s10388-023-01000-4","url":null,"abstract":"<p><strong>Background: </strong>Surgical resection of esophageal cancer is frequently performed to achieve a complete cure. However, the postoperative recurrence rate is 36.8-42.5%, leading to poor prognosis. Radiation therapy has been used to treat recurrences; solitary recurrence has been proposed as a prognostic factor for radiation therapy, though its significance is unclear. ¹⁸F-fluorodeoxyglucose positron emission tomography is a highly accurate diagnostic modality for esophageal cancer. This retrospective study aimed to analyze the outcomes of solitary postoperative recurrences of esophageal squamous cell carcinoma diagnosed with ¹⁸F-fluorodeoxyglucose positron emission tomography and treated with definitive radiation therapy.</p><p><strong>Methods: </strong>We examined 27 patients who underwent definitive radiation therapy for single or multiple postoperative recurrences of esophageal squamous cell carcinoma between May 2015 and April 2021. ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography was performed within 3 months before the commencement of radiation therapy. Kaplan-Meier, univariate, and multivariate analyses were performed to examine the overall survival and identify potential prognostic factors.</p><p><strong>Results: </strong>The 1-, 2-, and 3-year overall survival rates were 85.2%, 62.6%, and 47.3%, respectively, and solitary recurrence was the only significant factor associated with overall survival (P = 0.003). The 1-, 2-, and 3-year overall survival rates in patients with solitary recurrence were 91.7%, 80.2%, and 80.2%, respectively, and in patients with multiple recurrences they were 80.0%, 50.3%, and 25.1%, respectively. Multivariate analysis also showed solitary recurrence as a significant factor for overall survival.</p><p><strong>Conclusions: </strong>When diagnosed with ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography, solitary recurrence appears to have a more favorable prognosis than multiple recurrences.</p>","PeriodicalId":11918,"journal":{"name":"Esophagus","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10235149/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9580120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1.","authors":"Yuko Kitagawa,&nbsp;Ryu Ishihara,&nbsp;Hitoshi Ishikawa,&nbsp;Yoshinori Ito,&nbsp;Takashi Oyama,&nbsp;Tsuneo Oyama,&nbsp;Ken Kato,&nbsp;Hiroyuki Kato,&nbsp;Hirofumi Kawakubo,&nbsp;Hiroshi Kawachi,&nbsp;Shiko Kuribayashi,&nbsp;Koji Kono,&nbsp;Takashi Kojima,&nbsp;Hiroya Takeuchi,&nbsp;Takahiro Tsushima,&nbsp;Yasushi Toh,&nbsp;Kenji Nemoto,&nbsp;Eisuke Booka,&nbsp;Tomoki Makino,&nbsp;Satoru Matsuda,&nbsp;Hisahiro Matsubara,&nbsp;Masayuki Mano,&nbsp;Keiko Minashi,&nbsp;Tatsuya Miyazaki,&nbsp;Manabu Muto,&nbsp;Taiki Yamaji,&nbsp;Tomoki Yamatsuji,&nbsp;Masahiro Yoshida","doi":"10.1007/s10388-023-00993-2","DOIUrl":"https://doi.org/10.1007/s10388-023-00993-2","url":null,"abstract":"","PeriodicalId":11918,"journal":{"name":"Esophagus","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024303/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9629399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of endoscopic submucosal dissection for superficial esophageal cancer with esophageal varices.","authors":"Tatsuya Nakai,&nbsp;Tetsuya Yoshizaki,&nbsp;Shinwa Tanaka,&nbsp;Yoshinobu Yamamoto,&nbsp;Tomoya Sako,&nbsp;Yasuaki Kitamura,&nbsp;Takayuki Ose,&nbsp;Tsukasa Ishida,&nbsp;Atsushi Ikeda,&nbsp;Ryusuke Ariyoshi,&nbsp;Mineo Iwatate,&nbsp;Fumiaki Kawara,&nbsp;Toshitatsu Takao,&nbsp;Yoshinori Morita,&nbsp;Takashi Toyonaga,&nbsp;Yuzo Kodama","doi":"10.1007/s10388-023-01001-3","DOIUrl":"https://doi.org/10.1007/s10388-023-01001-3","url":null,"abstract":"<p><strong>Background: </strong>Heavy drinking is associated with esophageal cancer and esophageal varices. However, there are limited reports of endoscopic resection for esophageal cancer with esophageal varices. In this multicenter study, we clarified the safety and efficacy of endoscopic submucosal dissection for superficial esophageal cancer with esophageal varices.</p><p><strong>Methods: </strong>In this multicenter, retrospective, observational study, patients underwent esophageal endoscopic submucosal dissection at 10 referral centers in Japan from January 2013 to December 2019. We analyzed characteristics including backgrounds and varices, treatment outcomes, and adverse events in cases with esophageal varices.</p><p><strong>Results: </strong>A total of 1708 patients were evaluated, 27 (1.6%) of whom had esophageal varices. In patients with esophageal varices, the en bloc resection rate and R0 resection rate were 100% and 77.8%, respectively. Patients with esophageal varices had longer procedure times than patients without esophageal varices (p = 0.015). There was no significant difference in adverse events. There was no significant difference in procedure time and number of adverse events between patients who underwent pretreatment and those who did not. There was no significant difference in these outcomes for patients with lesions on varices compared to those without. Child-Pugh classification and location of the lesions also did not affect these outcomes.</p><p><strong>Conclusions: </strong>Esophageal cancer with esophageal varices could be treated endoscopically safely and effectively.</p>","PeriodicalId":11918,"journal":{"name":"Esophagus","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9629452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}